Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165860 | 0.92 | CA12 (0.38) | MAPTPOLBALDH1A1NPC1GAA | |
| SCHEMBL5168506 | 0.91 | MAPT (0.43) | MAPTPOLBALDH1A1NPC1GAA | |
| SCHEMBL5166116 | 0.85 | CA12 (0.37) | MAPTPOLBALDH1A1NPC1GAA | |
| SCHEMBL5179039 | 0.85 | CA12 (0.37) | MAPTPOLBALDH1A1NPC1GAA | |
| SCHEMBL5168055 | 0.84 | BDKRB1 (0.43) | MAPTPOLBALDH1A1NPC1GAA | |
| SCHEMBL5460988 | 0.84 | CA12 (0.36) | MAPTPOLBALDH1A1NPC1GAA | |
| SCHEMBL5179791 | 0.83 | BDKRB1 (0.39) | MAPTPOLBALDH1A1NPC1GAA | |
| SCHEMBL5469340 | 0.83 | BDKRB1 (0.39) | MAPTPOLBALDH1A1NPC1GAA | |
| SCHEMBL5179797 | 0.83 | BDKRB1 (0.39) | MAPTPOLBALDH1A1NPC1GAA | |
| SCHEMBL5179666 | 0.82 | CA12 (0.38) | MAPTALDH1A1CA12CA9HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299085-B2 | Quinazoline derivatives | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20070208018-A1 | Quinazoline Derivatives | NOVARTIS AG (CH) | 2007-09-06 | — | — | US | disclosed |
| EP-1773788-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS-PHARMA GMBH (AT) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006010591-A2 | QUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208018-A1 | Quinazoline Derivatives | CYP3A5, CYP3A7, CYP3A4 | MAPT 2053/4885POLB 3690/4885ALDH1A1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.